Skyhawk Therapeutics: Soaring Above the RNA Horizon

In this episode of BioTales, we uncover the remarkable story of Skyhawk Therapeutics – a biotech company with its wings firmly set on the frontiers of RNA biology. From a chance meeting on a humanitarian trip that sparked a revolutionary vision, to billion‑dollar collaborations with pharma giants, Skyhawk’s journey reads like a biotech thriller. We dive into the science of RNA splicing, the trials of launching a startup, and the promise of first‑in‑class, orally available medicines for Huntington’s disease, multiple myeloma and more. Tune in for the latest breaking news on Skyhawk’s $2 billion deal with Merck KGAA, and discover how three founders turned a dream of drugging the undruggable into reality.